argyrotsipi/train-dataset huggingface dataset:
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): Ninety per cent. of the adult population have had their first dose, and 8 million people have taken up the opportunity to have a booster jab. That is a successful vaccination programme, so I will take no lessons from the hon. Lady The hon. Lady talks about care homes and, from a personal point of view, I know how important it is to make sure our most vulnerable are vaccinated, which is why I am delighted that nine out of 10 care homes have had their jabs either delivered or booked. That is a great success This Government have already recognised that covid has exposed the disparities across the nation, which is why on 1 October we launched the Office for Health Improvement and Disparities to understand what is important and how we can make real change in our communities that need the most help The hon. Lady talks about bringing back retired medics and volunteers, but they are already back. They have been playing their part for months, and I take this opportunity to thank them for all their efforts. Just last week, I met a retired medic who had come back to St Thomas’ Hospital, and he was relishing his role in this amazing vaccination programme. The hon. Lady does those volunteers and returners a huge disservice I am always grateful to the hon. Lady and the right hon. Member for Leicester South (Jonathan Ashworth), because throughout this pandemic they have usually been co-operative, helpful and in agreement with us, but the hon. Lady’s remarks today give too little credit to the phenomenal role that the NHS and community pharmacies are already playing in the roll-out of our vaccination programme. They are delivering a booster programme of third doses while delivering the largest flu programme ever, with 35 million people now eligible for a flu jab. I call on people to come forward as soon as they can.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Jeremy Richard Streynsham Hunt (Conservative, Centre-right): My apologies, Mr Speaker, for missing the start of the Minister’s statement because you managed to expedite parliamentary business with commendable briskness this morning I thank the Minister for her update. Let me say how welcome it is that we have approved the new antiviral, molnupiravir—a new word for us to memorise—which could be immensely significant. When does she think we will be able to distribute it to people who have caught covid who are at home? She says that there is going to be a national study, which is potentially an important step. However, in a pandemic we sometimes bypass these national studies and go straight to distributing medicines that we know are safe to members of the public. Might this not be one of those occasions where we decide to speed things up? I also commend her efforts on the vaccine programme, but, as the shadow spokesman said, one reason we are behind other European countries on vaccinating teenagers is that the Joint Committee on Vaccination and Immunisation did not give its decision until September, whereas France was able to start vaccinating before the summer holidays. Is she looking at how we could speed up the JCVI processes? I appreciate that her hands are tied May I also ask the Minister to look at the booking system, because in parts of my constituency people are not able to book a booster jab until after they have passed the six-month mark? Would it not be better for anyone to be able to book their booster jab after they have passed the five-month mark? Finally, may I ask her when she is planning to tell the House about the very important decision on mandatory jabbing for NHS workers? That is a difficult decision. It is one I would support if the Government brought it to the House. I have read in the press that they are thinking of doing that in the spring, which mi well be the right timing, but this is something that NHS staff want to know about.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): I thank my right hon. Friend for his questions. I reiterate on the antivirals that we are working across government and the NHS to urgently get this treatment to patients. As he rightly says, it is important that we act very quickly. It was only earlier today that the Medicines and Healthcare products Regulatory Agency gave its approval, so we are already taking rapid steps in letting people know about this issue. He talked about the JCVI, for which I have huge respect. I do not think it is my position to intervene in its processes. We need robust processes to make sure that what we have available and the programmes we have are very safe, as the UK population would expect. He also talked about booking the booster. We always need to look at ways of improving accessibility, but we did open up the opportunity for people to go to walk-in centres for their booster, so that they do not need to book online or call 119. We are looking at ways of making this easier all the time. On the mandating of jabs, the Secretary of State will make an announcement in due course.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): I thank the hon. Lady for her update on what is happening in Scotland. I commend those involved in the roll-out of the vaccination programme in Scotland. We can all learn lessons from each other in this pandemic and it is only right that we do so. On the contracts the hon. Lady talked about, I will not comment on commercial decisions.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Lucy Allan (Conservative, Centre-right): I thank the Minister for her statement and the excellent work that she and her team are doing to roll out boosters as fast as possible. I urge her to consider whether bookings for boosters could be made in advance, so that people are already booked in when they become eligible and can immediately have their booster.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): The hon. Lady makes a very good point. I find it really concerning that one in six people in hospital with covid are unvaccinated pregnant women and it is an issue that I wholeheartedly want to address. I encourage every lady who is either looking to become or is pregnant to talk to their midwife and their GP and get reassurance that vaccines are safe for that cohort of ladies. The best thing they can do is to protect themselves and their babies.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Peter William Bone (Conservative, Centre-right): I got my jabs on time, I then managed to get covid—probably from this place—and I have also had my booster jab. I understand from the Minister that there is a new antiviral drug; how would that have been given to me when I was quite poorly with covid? When we have new drugs, can we give them easier names to pronounce?
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): My hon. Friend makes a good point: I do not know why the pharmaceutical companies come up with these tongue-tying names for their drugs. As I said earlier, we need to make sure that we roll out the new antiviral to the right people. The important and exciting thing is that the drug can be taken in people’s homes.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Duncan Charles Baker (Conservative, Centre-right): I recognise the enormous amount that is going into the booster programme and thank the Minister for that. In Norfolk and Waveney we are already up to nearly 55% of all eligible constituents having had their boosters, but my North Norfolk constituency has a particularly elderly demographic and we have no walk-in booster availability at all. I urge the Minister to put pressure on my local clinical commissioning group, given the worry it causes for the elderly demographic, to make sure that people can access walk-in booster jabs as quickly as possible.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): The hon. Lady raises an important issue. However, it is important that, for that individual whose GP is not able to give them a jab, they have words with their hospital consultant who may have more knowledge of their condition. I will definitely look into the system.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Andrew Hanson Jones (Conservative, Centre-right): I thank my hon. Friend for her statement. Delivering 8.7 million booster jabs at 2,400 vaccination sites is a great achievement. I agree entirely with the point about making booster jabs as available as possible. On that point though, in North Yorkshire, where we have had fantastic vaccine roll-out and take-up—it has been a great achievement—I am hearing mixed messages about what is happening in schools. The CCG has told me that they should be eligible for visits by the end of this month, but some schools have been reporting that they are not looking at visits until January or February next year by which stage, of course, it is too late. If I look at the website on the location of walk-in centres and tap in Harrogate, it brings up five locations in Halifax, which is about 17 miles away. Are there any problems with vaccine supply, or are we having some difficulties in North Yorkshire at the moment?
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): I can reassure my hon. Friend that there is no problem at all with the supply of vaccines; we have plenty of supply. He talks about schools. The vaccine programme in schools is being carried out by the school-aged immunisation service, which is very experienced in carrying out vaccinations for different conditions in schools. If there is a problem in his area, I will definitely look into it on his behalf.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): No death is acceptable and my condolences go to everyone who has lost somebody in this terrible pandemic. Our best wall of defence is through vaccinations. Vaccinations do work, so my message is: get your booster. If people have not had their first jab, they should get their first jab and continue to build that wall of defence.
Covid-19 Vaccinations — House of Commons, 2021-11-04
Topic: Health
Margaret Ann Throup (Conservative, Centre-right): I think it is important that everybody takes personal responsibility and makes sure that they protect themselves. As we know, people were shielding last winter, but we did not have this highly successful vaccination programme. The best way for people to protect themselves is to get jabbed, get protected and to protect themselves from the virus.
Afghanistan: Inquiry — House of Commons, 2021-11-04
Topic: Defense
Tobias Martin Ellwood (Conservative, Centre-right): I am grateful for the hon. Gentleman’s support. Is it worth his clarifying this point, which I did not? We have in our mind, as a yardstick, that an inquiry looks like Chilcot. Nobody is asking for Chilcot, but we are asking for something that I believe should be the norm: after every long-term military engagement, there is an assessment of what happened so that we can learn for the better. However, it does not need to take the legal approach that Chilcot was all about. That had a very different, complicated requirement.
Afghanistan: Inquiry — House of Commons, 2021-11-04
Topic: Defense
James Spencer Cleverly (Conservative, Centre-right): The Foreign, Commonwealth and Development Office takes very seriously the inquiries from Members from every part of the House, and we seek to answer them in a way that informs Members without compromising security or, sometimes, the discreet work that the Department has to do The simple fact is that multiple inquiries are being conducted by the Committees of the House into the functions of the Government. Indeed, my right hon. Friend the Member for Bournemouth East is leading the inquiry by the Defence Committee that will cover what happened after the US agreement with the Taliban in February 2020—the exact period of time that the hon. Member for Glasgow South mentions. It will also cover the planning and execution of the withdrawal of UK forces and the evacuation of UK nationals and Afghanistan nationals who worked with the British armed forces The Government’s view is that these initiatives offer ample scope to address the most important questions. The hon. Member for Aberavon, who knows that I have a huge degree of respect for him, has suggested a more limited inquiry—one that would be limited to a timescale that would prevent it from looking at the role his party might have played when it was in government. While the final stages of the deployment are important, if his proposal were to be taken forward, I think that people might see it as partisan and cynical. As the Prime Minister told the House on 8 July, we do not think an inquiry in addition to those multiple other inquiries is the right way forward.
Afghanistan: Inquiry — House of Commons, 2021-11-04
Topic: Defense
James Spencer Cleverly (Conservative, Centre-right): I will take the hon. Gentleman at his word. Being an honourable Member is not just some loose title; he is genuinely an honourable gentleman and I take him at his word The Government welcome the close interest in these events that the House has taken. We will study recommendations of the inquiries by the Foreign Affairs Committee, the Defence Committee and others with great care. The military campaign in Afghanistan over the past 20 years claimed the lives of 457 British service personnel, but we must never forget that it saved the lives of countless others. We can be proud of what we achieved, in step with our NATO allies, and today we are doing everything we can with our partners to protect those gains, to ensure the UK’s security and to help the Afghan people in their time of greatest need.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Crispin Jeremy Rupert Blunt (Conservative, Centre-right): A few of us have constituents with a child with epilepsy and have invested the time to get a detailed understanding of many of the issues. The problem, as alluded to by my right hon. Friend the Member for New Forest East (Dr Lewis), is that most of our colleagues think we have done it. After the decision was taken in November 2018—or when the licence was given for Billy Caldwell to get his medicine—the conclusion was that one would not be able to find anyone who was objecting, because if one can have medicine from the Asian poppy, why on earth can one not have medicine from cannabis? There was probably no opposition in this place at all. But the tragedy is that the evidence is that we have not done it. We must get back into the complexity. We will support the new Minister in fighting her corner to ensure that people can get these medicines, along with all the other interests that are engaged here too.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Crispin Jeremy Rupert Blunt (Conservative, Centre-right): I used that parallel as an example. I totally respect my hon. Friend’s point about licensing progress—of course she is correct—but this is about thinking imaginatively to work our way through the problems to the right solution. That applies desperately in this situation, as it did with Orkambi.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): Absolutely. The Government are committed to trying to resolve the blockage to licensing, which is the main factor hindering the prescription of these drugs. The Health and Social Care Secretary changed the law when he was Home Secretary, but that was not the end of the issue, and that is why we are taking these next steps. It is important not to dismiss the importance of licensed medication. We know from history that when medication that may have a good clinical effect is not tested thoroughly, there can be grave consequences, just as with thalidomide. The safety of a medicine is as important as its efficacy. I am not casting aspersions on cannabis, but the regulator has responsibility for all medicines, and it takes that issue very seriously.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): I take my right hon. Friend’s point. I will come on to that, and to timelines for the research that is in progress. Many of the products that we are talking about have not been licensed by any licensing authority across the world, including the Food and Drug Administration, the European Medicines Agency and our domestic MHRA. This is not just a UK problem; it is not the UK Government who are holding this back. As I said yesterday, I encourage manufacturers of these products to invest in clinical trials. Part of the Department’s work is providing funding for the National Institute for Health Research, which is actively opening its arms to charities, academics, researchers, manufacturers and third-sector organisations. Funding is available for clinical trials, if anyone wants to come forward with one, be it a randomised control trial, an observational study, a randomised control trial without a placebo arm, or a phase 1, 2 or 3 clinical study. The MHRA is willing to provide advice and support to any potential applicants who want to conduct a clinical trial or seek a licence for their medicines. There is funding and support; we need researchers to come forward with clinical trials.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): The hon. Gentleman makes an excellent point, and going forward we perhaps need to unblock some of the blockages in that area. I take that point on board Clinical trials and the licensing process provide evidence and information that doctors rely on to support their treatment decisions. Many clinicians have fed back that they are reticent to prescribe these products until there is more evidence, because ultimately they are responsible for their patients when it comes to a treatment’s safety and effectiveness. Doctors are particularly unwilling, given the THC element of cannabis products; there is some emerging data and evidence of harm, particularly to children, including effects on the developing brain and heart. That is why the evidence base is so crucial, but I am happy—I say this especially to the hon. Member for Manchester, Withington, who sponsors the Medical Cannabis (Access) Bill—to consider what blockages could be unblocked to speed that process up Doctors are right to be cautious when prescribing any product if they are not confident in the evidence base. As I said yesterday, I am clear that prescription remains a clinical decision, as does prescription of any medication. It would be inappropriate for the Government to force clinicians to prescribe a medicine, but we will try to unblock some of the licensing blockages Let me highlight some of the studies that are starting to take off. This might have been mentioned, but from 1 April we have the establishment of clinical trials for NHS England and the NIHR. We have introduced a national patient registry, which will record patient outcomes, with a view to its being rolled out across the devolved Administrations. It is England-only at the moment. We are aiming to record the data of those who receive the medicines, and to consider side-effects, efficacy and a whole range of issues, in order to support clinicians working with patients, and to start to build an evidence base In addition, a randomised control trial is being set up. It has three arms, which will include one arm with CBD or THC, and one arm with a placebo. We expect it to open fairly soon. Those looking to access these drugs—children in particular—will be able to do so in a blinded way and can take part in the study. If the data come through relatively quickly, that will open up opportunities to submit evidence to the MHRA.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): I take the hon. Gentleman’s point, but many children are not accessing this medication, and this is a route to that. As I explained in yesterday’s debate, clinical randomised control trials with a placebo arm have extremely strict rules, and if one arm of the study is showing incredible progress and doing better than the other arms, the study must be stopped, patients unblinded, and everyone switched to the arm that is doing the best. In some circumstances, that has enabled people to access drugs under clinical research in a much quicker way. It does have some advantages.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): I take the hon. Lady’s point, but the MHRA, which is the regulator, and other regulators around the world have a tier of research that they will accept. The randomised controlled trial method is the gold standard, and the more randomised controlled data someone has, the more likely they are to get a trial approved quickly. Of course observational studies will be used. That is why, if researchers have a large group, want to do observational studies—we heard about the Sapphire clinic from the hon. Member for Inverclyde—and come forward with observational data, I encourage them to speak to the MHRA to see whether that is the sort of research that would be acceptable. It is important that they have those discussions with the regulating body, because it may well accept some of that evidence Until manufacturers, researchers, academics and those using these drugs in practice come forward with whatever research they feel would be acceptable and have those discussions, we will go round in a circle. I am keen that if observational studies are acceptable, we support them to happen. Whatever it takes, in research terms, to get a licence through, the Government are there, providing funding, advice and support. However, ultimately, they are not the body that can make that decision; but I think there is a willingness around the House to try to find a resolution It will take time to generate further evidence and see the results of clinical trials. The Health Secretary and I are committed to doing everything in our power to accelerate this work. There have been some helpful suggestions this afternoon that we may need to go away and look at I thank everyone again. Although this is the second debate on this subject in two days, I know that it will not be the last; the private Member’s Bill will come forward next month. I want to put on the record my commitment to this issue. It is extremely difficult. In yesterday’s debate, we heard constituents’ stories relayed by their MPs, including the hon. Member for Middlesbrough (Andy McDonald). They really are very moving testaments, and we want to find a way forward. We have changed the law, but that has clearly not been enough. We need to find a resolution, so that we can get these medications licensed if the clinical evidence is there, and we need to work with the regulator.
Medical Cannabis: Alleviation of Health Conditions — House of Commons, 2021-11-04
Topic: Health
Maria Colette Caulfield (Conservative, Centre-right): The hon. Lady makes a good point. If there are clinicians who want to take a lead on this, there is obviously scope to look at that, but we must be clear that we have to license and support research for this medicine in the way we would any other. I have given a commitment today to working with hon. Members on both sides of the House to demonstrate how seriously the Government take this issue.